Person:
ÖZGEN, ZÜLEYHA

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

ÖZGEN

First Name

ZÜLEYHA

Name

Filters

2013 - 20194
Reset filters

Settings

Start date: 2013 × End date: 2019 × Has files: true ×

Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    PublicationOpen Access
    Demographic, clinical and treatment characteristics of patients with Kaposi's sarcoma: A single-center study
    (MARMARA UNIV, FAC MEDICINE, 2019-05-29) SALMAN, ANDAÇ; Salman, Andac; Ozgen, Zuleyha
    Objective: The clinical, demographic and treatment characheristics of patients with Kaposi's sarcoma (KS) are not well-detined. There is lack of consensus on treatment modalities. Thus, we aimed to define demographic, clinical characteristics and treatment outcomes in our cohort of patients with KS. Patients and Methods: A retrospective cohort study was done and all patients who were followed up in our specialized cutaneous tumors outpatient clinic with a diagnosis of KS between 2006 and 2018 were included in the study. Results: A total of 25 patients were included in the study. The mean age of the patients was 66 and 80% were male. The most common form of KS was classic type (80%). During a mean follow-up of 43 months, the most frequently administered treatments were cryotherapy, interferons, radiotherapy, topical imiquimod and topical timolol. Overall a complete response was observed in 9 (36%) patients. Conclusion: The clinical and demographic characteristics of our cohort match those observed in existing literature. We think that the use of local treatments such as cryotherapy, topical imiquimod should be used more frequently in patients with limited disease. Considering the efficacy of timolol in other vascular tumors, future prospective studies investigating the effects of timolol in KS are highly warranted.
  • Thumbnail Image
    PublicationOpen Access
    Growth Arrest-Specific 6 and Cardiometabolic Risk Factors in Patients with Psoriasis
    (WILEY, 2015-04) SEÇKİN GENÇOSMANOĞLU, DİLEK; Sunbul, Murat; Cagman, Zeynep; Gerin, Fethullah; Ozgen, Zuleyha; Durmus, Erdal; Seckin, Dilek; Ahmad, Sarfraz; Uras, Fikriye; Agirbasli, Mehmet
    ObjectivesAn increased risk for cardiovascular disease with psoriasis has been reported. Growth Arrest-Specific 6 (GAS6) amplifies pro-inflammatory endothelial cell activation via TAM receptors. However, it also inhibits inflammation by multiple mechanisms including phagocytosis. The objective of this study was to investigate whether plasma GAS6 levels are associated with conventional cardiometabolic (CM) risk factors in patients with psoriasis. MethodsForty patients diagnosed with psoriasis (22 male, mean age: 43.313.8years) and 40 age-/sex-matched healthy controls (22 male, mean age: 39.38.9years) were included in the study. CM risk factors (hypertension, hyperlipidemia, diabetes mellitus, and cigarette smoking) were identified. GAS6 levels were measured by ELISA. ResultsThere were no significant differences between the plasma GAS6 levels of patients with psoriasis compared to the control group (6.6 +/- 2.0ng/mL, 7.6 +/- 2.8ng/mL, respectively, P>0.05). However, GAS6 levels of patients with psoriasis having a smoking history (n=11) were significantly lower than both patients with psoriasis who had no smoking history (n=29) and controls (5.5 +/- 1.7ng/mL, 6.9 +/- 1.9ng/mL, 7.6 +/- 2.8ng/mL, respectively, P<0.05). Similarly, psoriasis patients with at least one CM risk factor showed lower GAS6 levels compared to subjects without any CM risk factor (5.7 +/- 1.7ng/mL, 7.3 +/- 2.0ng/mL, P<0.01). There was no correlation between the GAS6 level, disease duration or PASI score (r=0.150, -0.150, and P=0.310, 0.398, respectively). ConclusionsThis pilot study provides the first evidence in humans for an association between low plasma GAS6 levels and conventional risk factors in psoriasis. Further large scale, prospective studies are needed to confirm these results.
  • Thumbnail Image
    PublicationOpen Access
    Effect of Dental Follicle Mesenchymal Stem Cells on Th1 and Th2 Derived Naive T Cells in Atopic Dermatitis Patients
    (MARMARA UNIV, INST HEALTH SCIENCES, 2019-08-31) GÖKER, MEHMET KAMİL; Zibandeh, Noushin; Genc, Deniz; Ozgen, Zuleyha; Duran, Yazgul; Kasap, Nurhan; Goker, Kamil; Baris, Safa; Ergun, Tulin; Akkoc, Tunc
    Objective: The purpose of our study is to investigate the immunomodulatory effects of Dental Follicle Mesenchymal Stem Cells (DF-MSCs) on lymphocytes isolated from peripheral blood of Atopic Dermatitis (AD) patients, a Th2 disease and psoriasis, a Th1 / Th17 disease and compare them with healthy individuals in vitro. Methods: Patients with the AD (n = 9) and psoriasis (n = 6) who are followed up in Marmara University Pediatric Allergy and Immunology and Dermatology outpatient clinics and healthy subjects (n = 6) were included. Peripheral Blood Mononuclear Cells (PBMCs) were isolated from 20 ml of venous blood of all participants. Cells were cultured for 72 hours in the absence and presence of DF-MSCs with anti-CD3/anti-CD28 stimulation or without stimulation. At the end of this period, CD4+ and CD8+ T lymphocyte proliferation and cytokine levels from the culture supernatants were analyzed by flow cytometry. Results: In the presence of DF-MSCs, proliferation ratio was suppressed in both CD4+ and CD8+ cells in AD and psoriasis patients (p<0,05). IFN-gamma levels significantly increased in AD patients in the presence of DF-MSCs (p<0,05) whereas decreased significantly in psoriasis patients in the presence of DF-MSCs (p<0,05). IL-4 levels significantly decreased in AD patients in the presence of DF-MSCs (p<0,05) but remained unchanged in psoriasis patients (p>0,05). IL-10 increased significantly in both groups in the presence of DF-MSCs (p<0,05). Conclusion: Our results support immunoregulatory effects of DF-MSCs on both AD and psoriasis which are Th2 and Th1 / Th17 dominant diseases respectively. Our evidence-based results demonstrated that DF-MSCs could have a beneficial therapeutic implication for inflammatory skin diseases.
  • Thumbnail Image
    PublicationOpen Access
    Immunmodulation in the treatment of dermatological diseases
    (TURKISH SOC DERMATOLOGY VENEROLOGY, 2013-09-05) SEÇKİN GENÇOSMANOĞLU, DİLEK; Ozgen, Zuleyha; Seckin, Dilek
    Immunological effects have an important role in the action mechanisms of the majority of topical and systemic agents, and even some physical treatment modalities in dermatology. Depending on the disease being treated, these effects may be suppression or stimulation of the immune system as well as modulation of the existing functions. Agents that show their effects mainly by immunmodulation in the treatment of dermatological diseases are discussed in the present article. Treatment alternatives included in the article, azathioprine, mycophenolate mofetil, cyclosporine, glucocorticosteroids, topical calcineurin inhibitors, photo(chemo)therapy, intravenous immunoglobuline, interferon, rituximab, omalizumab, imiquimod and extracorporeal photopheresis are discussed focusing especially on their immunomodulatory effects without any mention on their prescribing details, treatment protocols and monitorization aspects.